| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 09/25/2003 | WO2003078415A1 Cyclic hemiacetal derivative and use thereof |
| 09/25/2003 | WO2003078413A1 Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity |
| 09/25/2003 | WO2003078409A1 Carboxyoic acid compounds and drugs containing the compounds as the active ingredient |
| 09/25/2003 | WO2003078404A1 Pyrimidine derivatives |
| 09/25/2003 | WO2003078403A2 Derives d’aminoindazoles comme inhibiteurs de proteine-kinase |
| 09/25/2003 | WO2003078401A1 Preventive and/or therapeutic agent for hypoxic ischemic brain disorder |
| 09/25/2003 | WO2003078395A1 Piperidine derivatives useful as modulators of chemokine receptor activity |
| 09/25/2003 | WO2003078394A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators |
| 09/25/2003 | WO2003077949A2 Methods of treating diabetes using pde 11a inhibitors |
| 09/25/2003 | WO2003077947A1 Methods of modulating cd200 receptors |
| 09/25/2003 | WO2003077940A1 Chemical igf-i composition for the treatment and prevention of neurodegenerative diseases |
| 09/25/2003 | WO2003077929A1 Fosinopril formulation |
| 09/25/2003 | WO2003077921A1 Azinylaminoazoles as inhibitors of protein kinases |
| 09/25/2003 | WO2003077919A1 Fluorinated 4-azasteroid derivatives as androgen receptor modulators |
| 09/25/2003 | WO2003077916A1 Use of proton pump inhibitors for the treatment of noncardiac chest pain |
| 09/25/2003 | WO2003077915A1 Use of rapamycin for inhibiting of cell death |
| 09/25/2003 | WO2003077914A1 N3 alkylated benzimidazole derivatives as mek inhibitors |
| 09/25/2003 | WO2003077910A1 Methods of treatment with selective ep4 receptor agonists |
| 09/25/2003 | WO2003077908A1 Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension |
| 09/25/2003 | WO2003077904A1 Biological activity-promoting compositions containing soybean germ-origin isoflavone aglycon |
| 09/25/2003 | WO2003077901A1 Preventing and/or treating cardiovascular disease and/or associated heart failure |
| 09/25/2003 | WO2003077898A1 Agents for corneal or intrastromal administration to treat or prevent disorders of the eye |
| 09/25/2003 | WO2003077897A1 Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes |
| 09/25/2003 | WO2003077892A2 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide for treating ang ii-mediated diseases |
| 09/25/2003 | WO2003077865A2 Methods and compositions for directing cells to target organs |
| 09/25/2003 | WO2003077864A2 Methods and compositions for directing cells to target organs |
| 09/25/2003 | WO2003077847A2 Substituted amides |
| 09/25/2003 | WO2003077840A2 Method of modulating inflammatory response |
| 09/25/2003 | WO2003077832A2 Dexanabinol and dexanabinol analogs regulate inflammation related genes |
| 09/25/2003 | WO2003077723A2 Methods and devices for detection and therapy of atheromatous plaque |
| 09/25/2003 | WO2003077657A1 Choline-silicic acid complex with osmolytes and divalent trace elements |
| 09/25/2003 | WO2003070738A3 Topiramate salts and compositions comprising and methods of making and using the same |
| 09/25/2003 | WO2003068171A3 Method and composition for treatment of inflammation and aids-associated neurological disorders |
| 09/25/2003 | WO2003042411A3 Use of mutations of mec-1 and its related genes in the identification of compounds for treatment of disease |
| 09/25/2003 | WO2003039472A3 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process |
| 09/25/2003 | WO2003039451A3 Thiazole pyridazinones as adenosine antagonists |
| 09/25/2003 | WO2003029199A9 Benzene derivatives, process for preparing the same and use thereof |
| 09/25/2003 | WO2003015690A3 Method for treating primary insomnia |
| 09/25/2003 | WO2003013530A3 Salts of substituted 1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid derivatives as nmda antagonists |
| 09/25/2003 | WO2003011855A3 Pyrazole-derived kinase inhibitors and uses thereof |
| 09/25/2003 | WO2003008454A3 Glycoprotein vi fusion proteins |
| 09/25/2003 | WO2002102375A3 Imidazole derivatives for modulating sodium channels |
| 09/25/2003 | WO2002100412A3 Stabilized dispersion of phytosterol in oil |
| 09/25/2003 | WO2002096357A3 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| 09/25/2003 | WO2002094287A3 Identifying parasitic fungi of the organism, and treatment thereof |
| 09/25/2003 | WO2002080911A3 Use of substituted imidazo[1,2-a]-pyridine-3-yl-amide and imidazo[1,2-a]-pyridine-3-yl-amine compounds as medicaments for the treatment of neurodegenerative diseases |
| 09/25/2003 | WO2002080847A3 Use of tumor necrosis factor inhibitors to treat cardiovascular disease |
| 09/25/2003 | WO2002077263A3 Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon |
| 09/25/2003 | WO2002076482A3 USE OF IKK-β INHIBITORS AND METHOD FOR DISCOVERY OF SAID INHIBITORS |
| 09/25/2003 | WO2002063004A3 G-protein coupled receptors |
| 09/25/2003 | WO2002046419A3 Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins) |
| 09/25/2003 | WO2002036573B1 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents |
| 09/25/2003 | WO2002036161A3 Novel targeted compositions for diagnostic and therapeutic use |
| 09/25/2003 | WO2002032842A3 Compounds with high monoamine transporter affinity |
| 09/25/2003 | WO2002030884A3 Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
| 09/25/2003 | WO2002030882A3 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| 09/25/2003 | WO2002028355A3 Methods and compositions for enhancing angiogenesis |
| 09/25/2003 | WO2002026982A3 Secreted human proteins |
| 09/25/2003 | WO2002024910A3 Isolated human transporter proteins, nucleic acid molecules encoding them, and uses thereof |
| 09/25/2003 | WO2002014368A3 Proteins and nucleic acids encoding the same |
| 09/25/2003 | WO2002004433A3 Melanin concentrating hormone receptor ligands |
| 09/25/2003 | US20030181765 Reacting an azide compound with an amine to form an intermediate, reducting the azide of the intermediate to form amine; amidation, reduction of azide, azidation, blocking hydroxy group, lactonization and deblocking |
| 09/25/2003 | US20030181728 Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 09/25/2003 | US20030181661 Gridlock nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 09/25/2003 | US20030181658 Exhibit protease activity as a single chain or as an activated two chain form; use of polypeptides to identify compounds that modulate the protease activity thereof and as tumor markers |
| 09/25/2003 | US20030181587 Thermoplastic resin composition |
| 09/25/2003 | US20030181527 Novel formulations of alpha-2,4-disulfophenyl-n-tert-butylnitrone |
| 09/25/2003 | US20030181519 Substituted phenyl naphthalenes as estrogenic agents |
| 09/25/2003 | US20030181514 Therapeutic compounds and methods |
| 09/25/2003 | US20030181507 Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators |
| 09/25/2003 | US20030181502 Methods of treating sepsis |
| 09/25/2003 | US20030181500 For therapy and prophylaxis of cardiac failure, the prevention of ischemic coronary heart disease or recurrence of ischemic coronary heart disease |
| 09/25/2003 | US20030181498 For therapy of disease mediated by interation of Vascular Cell Adhesion Molecule-1 (VCAM-1) and/or fibronectin and integrin receptor and/or alpha 4 beta 1 |
| 09/25/2003 | US20030181497 Heterocyclic acridone inhibitors of IMPDH enzyme |
| 09/25/2003 | US20030181485 A (2-methyl-3-pyridinyl)oxy)-3-pyridinyl)urea derivatives for treatment of a disease or disorder of the central nervous system, medical diagnosis |
| 09/25/2003 | US20030181481 Therapeutic drugs for treating central nervous system disorders |
| 09/25/2003 | US20030181477 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor |
| 09/25/2003 | US20030181476 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereof |
| 09/25/2003 | US20030181469 Crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound |
| 09/25/2003 | US20030181458 Preferential serotonin receptors antagonists comprising heterocyclic amines used for prophylaxis or prevention of headaches, sleep, sexual or eating disorders and as antidepressants |
| 09/25/2003 | US20030181457 Tertiary amides used as preferential inhibitors of cyclic guanosine 3',5'-monophosphate specific phosphodiesterase, for prophylaxis of cardiovascular and sexual disorders |
| 09/25/2003 | US20030181454 Nitrogen compounds and prodrugs used as type-II secretory phospholipase(sPLA2) agonists or antagonists, for prevention cancer, cirrhosis, Alzheimer's disease and/or arteriosclerosis |
| 09/25/2003 | US20030181450 Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments |
| 09/25/2003 | US20030181446 Novel N-acylated heterocycles |
| 09/25/2003 | US20030181445 Administering compounds such as N-(3-(5-Cyano-1-(4-fluoro-phenyl)-1,3-dihydroisobenzofuran-1-yl)-1 -propyl)glycine ethyl ester, for prophylaxis of psychological disorders |
| 09/25/2003 | US20030181444 Heterocyclic amines such as 4-(3,4-dichlorophenyl)-2-(2-(4-methylpiperazin-1-yl)-benzylidene) -thiomorpholin-3-one, used as antiserotonine agents |
| 09/25/2003 | US20030181441 Tumor necrosis factor-alpha converting enzyme antagonists, such as (2S,3S)-4-(4-(3,5-difluro-benzyloxy)-benzenesulfonyl) -2-methyl-thiomorpholine-3-carboxylic acid hydroxyamide, used as antiarthritic or anticarcinogenic agents |
| 09/25/2003 | US20030181439 Use of paullone derivatives for making medicines |
| 09/25/2003 | US20030181438 Bicyclic lactam derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) |
| 09/25/2003 | US20030181422 Cardioprotective phosphonates and malonates |
| 09/25/2003 | US20030181421 Method of administering bisphosphonates |
| 09/25/2003 | US20030181420 Modulators of LXR |
| 09/25/2003 | US20030181417 Nitroderivatives of polysaccharides |
| 09/25/2003 | US20030181389 Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds |
| 09/25/2003 | US20030181388 Formula I are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire |
| 09/25/2003 | US20030181373 Vascular relaxation inhibitors. Vascular relaxation agents comprising PTHrP or a fragment thereof and vascular relaxation inhibitors comprising a substance capable of inhibiting the binding between PTHrP and a receptor thereof. |
| 09/25/2003 | US20030181362 Receptor |
| 09/25/2003 | US20030181352 Substituted heterocyclic compounds |
| 09/25/2003 | US20030180934 Plasminogen-like polynucleotides, polypeptides, and antibodies |
| 09/25/2003 | US20030180931 Cellubrevin homologs |